Effectiveness of the BNT162B2 vaccine after recovery from CoviD-19

Ariel Hammerman, Ruslan Sergienko, Michael Friger, Tanya Beckenstein, Alon Peretz, Doron Netzer, Shlomit Yaron, Ronen Arbel

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

BACKGROUND The risk of infection with severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) decreases substantially among patients who have recovered from coronavirus disease 2019 (Covid-19). However, it is unknown how long protective immunity lasts. Current guidelines recommend vaccination of recovered patients even though data regarding vaccine effectiveness in such cases are still limited. METHODS In this retrospective cohort study, we reviewed electronic medical records from a large health care organization in Israel to assess reinfection rates in patients who had recovered from SARS-CoV-2 infection before any vaccination against Covid-19. We compared reinfection rates among patients who had subsequently received the BNT162b2 vaccine (Pfizer–BioNTech) and those who had not been vaccinated between March 1 and November 26, 2021. We used a Cox proportional-hazards regression model with time-dependent covariates to estimate the association between vaccination and reinfection after adjustment for demographic factors and coexisting illnesses. Vaccine effectiveness was estimated as 1 minus the hazard ratio. In a secondary analysis, we evaluated the vaccine effectiveness of one dose as compared with two doses. RESULTS A total of 149,032 patients who had recovered from SARS-CoV-2 infection met the eligibility criteria. Of these patients, 83,356 (56%) received subsequent vaccination during the 270-day study period. Reinfection occurred in 354 of the vaccinated patients (2.46 cases per 100,000 persons per day) and in 2168 of 65,676 unvaccinated patients (10.21 cases per 100,000 persons per day). Vaccine effectiveness was estimated at 82% (95% confidence interval [CI], 80 to 84) among patients who were 16 to 64 years of age and 60% (95% CI, 36 to 76) among those 65 years of age or older. No significant difference in vaccine effectiveness was found for one dose as compared with two doses. CONCLUSIONS Among patients who had recovered from Covid-19, the receipt of at least one dose of the BNT162b2 vaccine was associated with a significantly lower risk of recurrent infection.

Original languageEnglish
Pages (from-to)1221-1229
Number of pages9
JournalNew England Journal of Medicine
Volume386
Issue number13
Early online date16 Feb 2022
DOIs
StatePublished - 31 Mar 2022

ASJC Scopus subject areas

  • Medicine (all)

Fingerprint

Dive into the research topics of 'Effectiveness of the BNT162B2 vaccine after recovery from CoviD-19'. Together they form a unique fingerprint.

Cite this